Functional performance of the combination product is significantly influenced by the interactions between the drug product and its primary container closure system. Ana Rusetski, Senior Manager, Device Development at Astria Therapeutics discusses Astria Therapeutic’s data-driven strategy to evaluate drug-container compatibility in early development to de-risk potential future issues.
Lead Editorial
De-risking Combination Product Development Through Early Data-Driven Evaluation of Container Closure Systems
